Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer.

Anca Chelariu-RaicuCharles F LevenbackBrian M SlomovitzJudith WolfDiane C BodurkaJohn J KavanaghChristopher MorrisonDavid M GershensonRobert L Coleman

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2020)

Although the drug combination was relatively well tolerated, this prospective phase Ib/II clinical trial did not show sufficient clinical activity of topotecan combined with gefitinib in patients with epidermal growth factor receptor positive recurrent ovarian, fallopian tube, or peritoneal cancers.

Keyphrases

epidermal growth factor receptor
tyrosine kinase
advanced non small cell lung cancer
clinical trial
small cell lung cancer
papillary thyroid
randomized controlled trial
study protocol
childhood cancer
emergency department
drug induced
lymph node metastasis
phase iii